Nimbus Therapeutics pulls in $43 mln

Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company’s previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.

Sqrrl grabs $7 mln in Rally Ventures-led round

Cambridge, Massachusetts-based big data analytics company Sqrrl has raised $7 million in Series B funding. Rally Ventures led the round with participation from previous backers Atlas Venture and Matrix Partners.

110 Views

Art tech startup Cuseum snags $1.2 mln seed

Boston-based art tech startup Cuseum has raised $1.2 million in seed funding. The investors included Foundry Group’s FG Angels, Atlas Venture’s Boston Syndicates, Seavest Capital Partners, Drummond Road Capital and New Gen Partners.

112 Views

The Medicines Company buys Annovation Biopharma

The Medicines Company said Wednesday it acquired all the outstanding equity of Annovation Biopharma, a portfolio company of Atlas Venture. Financial terms weren’t announced. Cambridge, Massachusetts-based Annovation aims to create safer therapies for anesthesia and critical care.

114 Views

LTI picks up $20 mln Series A

Cambridge, Massachusetts-based Lysosomal Therapeutics Inc, which develops molecules to treat neurodegenerative diseases, has closed $20 million in Series A funding. The backers in this round included Atlas Venture, Hatteras Venture Partners, Lilly Ventures, Sanofi-Genzyme BioVentures, Roche Venture Fund, Partners Innovation Fund and Orion Equity Partners.

122 Views

Button sews up $12 mln Series A

Redpoint Ventures has led a $12 million Series A funding round for Button, the latter announced in a post on its site. Other investors that participated in the round included Greycroft, DCM, Atlas Venture, VaynerRSE, Slow Ventures and NBA Commissioner Emeritus David Stern. Also, Redpoint’s Chris Moore has been appointed to Button’s board. Based in New York City, Button is a provider of customer acquisition and retention solutions for apps. To read the announcement, visit here.

110 Views

Surface Oncology attracts $35 mln Series A

Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.

158 Views

Par80 snags $10.5 mln Series A

Par80, a healthcare operating system platform provider, has closed $10.5 million in Series A funding. The investors included Atlas Venture, Founder Collective and CHV Capital.

Appcues scores $1.2 mln seed

Appcues has secured $1.2 million in seed funding. The investors included Atlas Venture. Based in Boston, Appcues is an SaaS platform for user onboarding.

Appcito nets $7.5 mln Series A

Santa Clara, Calif.-based Appcito, a cloud application infrastructure firm, has received $7.5 million in Series A funding. The backers included March Capital Partners and Atlas Venture.

151 Views

Nashville start-up Overdog picks up $1.8 mln

Overdog has raised $1.8 million in financing in a round led by Atlas Venture and Chicago Ventures. Other investors included Zynga co-founder Mark Pincus, United Talent Agency and Mountain Group Capital. In conjunction with the funding, Chicago Ventures’ Stuart Larkins has been added to Overdog’s board of directors. Based in Nashville, Overdog is a console matchmaking app developer.

111 Views

Intellia Therapeutics collects $15 mln

Intellia Therapeutics has received $15 million in Series A financing. Atlas Venture and Novartis led the round. Intellia develops therapeutic products for gene editing and repair.

162 Views

3D firm Paracosm attracts $3.3 mln seed

3D firm Paracosm has closed $3.3 million in seed funding. Atlas Venture led the round with participation from other investors that included iRobot, Osage University Partners, BOLDstart Ventures, New World Angels and Deep Fork Capital.

VC-backed Raze Therapeutics names new VP

Raze Therapeutics has hired Dr. Mikel Moyer as vice president of molecular discovery. The appointment becomes effective November 1. Based in Cambridge, Mass., Raze Therapeutics is a biotech firm focused on developing new cancer drugs. Its backers include Atlas Venture, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis.

130 Views

Quartet Medicine scores $17 mln Series A

Quartet Medicine has closed $17 million in Series A financing. Atlas Venture led the round with participation from Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund. In conjunction with the funding, Henry Skinner of Novartis Venture Funds has been appointed to Quartet’s board of directors. Based in Cambridge, Mass., Quartet is a biotech firm focused on treating chronic pain and inflammation.

195 Views

Unum Therapeutics scores $12 mln Series A

Unum Therapeutics has received $12 million in Series A funding. Fidelity Biosciences and Atlas Venture led the round with participation from Sanofi-Genzyme BioVentures. Headquartered in Cambridge, Mass., Unum Therapeutics is developing cellular immunotherapy to treat cancer.

PE HUB Community

Join the 12514 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget